Icon
+91 94997 68112
Login Register

OTEZLA XR - (75MG, 10MG, 20MG)

APREMILAST None
75MG, 10MG, 20MG
Less Than $1000 mn
None None
None None
None None
OTEZLA/OTEZLA XR, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with: • Active psoriatic arthritis • Plaque psoriasis who are candidates for phototherapy or systemic therapy • Oral ulcers associated with Behçet’s Disease. Pediatric patients 6 years of age and older with: • Active psoriatic arthritis • Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In the pediatric population, OTEZLA is indicated for patients weighing at least 20 kg, and OTEZLA XR is indicated for patients weighing at least 50 kg.
Yes
OTEZLA XR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** *********

OTEZLA XR - (75MG)

APREMILAST None
75MG
Less Than $1000 mn
None None
None None
None None
None
No
OTEZLA XR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.